Pharmacyclics Inc (PCYC)

PCYC (NASDAQ:Drugs) EQUITY
$230.48
pos +13.72
+6.33%
Today's Range: 216.47 - 232.40 | PCYC Avg Daily Volume: 1,171,600
Last Update: 03/04/15 - 4:00 PM EST
Volume: 2,624,339
YTD Performance: 77.30%
Open: $217.26
Previous Close: $216.77
52 Week Range: $82.51 - $231.09
Oustanding Shares: 76,016,912
Market Cap: 16,821,782,456
6-Month Chart
TheStreet Ratings Grade for PCYC
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 5 9 10 10
Moderate Buy 0 0 0 0
Hold 9 5 5 5
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.29 1.71 1.67 1.67
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 201.17
Price Earnings Comparisons:
PCYC Sector Avg. S&P 500
201.17 200.80 27.72
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
55.58% 57.92% 736.93%
GROWTH 12 Mo 3 Yr CAGR
Revenue 180.50 87.63 3.39
Net Income 28.50 -3.45 0.00
EPS 26.80 -2.93 0.00
Earnings for PCYC:
EBITDA 0.13B
Revenue 0.73B
Average Earnings Estimates
Qtr (03/15) Qtr (06/15) FY (12/15) FY (12/16)
Average Estimate $0.08 $-0.59 $0.27 $4.01
Number of Analysts 7 7 10 9
High Estimate $0.25 $0.43 $1.76 $7.96
Low Estimate $-0.21 $-1.36 $-1.24 $0.85
Prior Year $0.23 $-0.49 $1.09 $0.27
Growth Rate (Year over Year) -66.46% -20.99% -75.14% 1,381.34%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Sector could regain its leadership role.
Bearish
Mar 03, 2015 | 8:13 AM EST
PCYC was downgraded from Outperform to Neutral, Wedbush said. $234 price target. Valuation call, as the company is largely pricing in p...
It's almost comical how welcoming it is these days.
Bearish
Feb 27, 2015 | 8:00 AM EST
PCYC was downgraded from Outperform to Neutral, Credit Suisse said. Valuation call, based on takeover speculation and a $233 price targ...

A Tough Day to Be Short Real Money Pro($)

Two stocks that could hurt your portfolio.
Bullish
Feb 19, 2015 | 7:59 AM EST
PCYC was upgraded from Neutral to Buy, Nomura said. $196 price target. Higher CLL demand could drive earnings upside. 
Bearish
Feb 19, 2015 | 7:26 AM EST
PCYC was downgraded from Overweight to Neutral, JP Morgan said. $173 price target. Valuation call, as the stock is up 39% year-to-date....
Bullish
Jan 22, 2015 | 6:41 AM EST
Shares of PCYC now seen reaching $253, according to JMP Securities. Estimates also increased, given the company's new domestic sales gu...

How to Build a Portfolio Real Money Pro($)

It's crucial to avoid being a 'closet indexer'.
Bullish
Nov 05, 2014 | 7:01 AM EST
Shares of PCYC now seen reaching $175, according to Nomura. Estimates also upped, given higher expected Imbruvica results. Buy rating.&...

Columnist Conversations

Equities post their second day of losses and are now down for the month. Oil rebounds after positive comments...
The tug of war on the 30-minute chart continues. Please refer to today's article for more info. Here is the u...
$415 million to the buy side.
I have modestly raised my net short exposure today.

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.